Anginera™, three-dimensional fibroblast culture: Clinical path to treating cardiac ischemia

Pharmaceuticals Policy and Law

Volumn 12, Issue 1-2, 2010, Pages 147-149

  Siani Rose, Michael ^a  

^a Theregen Inc   (United States)

Author keywords

Anginera ; fibroblast; small vessel disease

Indexed keywords

CARDIAC PATIENT; CELL THERAPY; CORONARY ARTERY BYPASS GRAFT; ECHOCARDIOGRAPHY; FIBROBLAST CULTURE; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE WALL; HUMAN; IMMUNOHISTOCHEMISTRY; PATIENT SAFETY; PRIORITY JOURNAL; SHORT SURVEY;

EID: 78049413989     PISSN: 13892827     EISSN: None     Source Type: Journal    
DOI: 10.3233/PPL-2010-0289     Document Type: Short Survey

References (3)

1. J. Mansbridge, K. Liu, E. Pinney et al., Growth factors secreted by fibroblasts: role in healing diabetic foot ulcers. Diabetes, Obesity andMetabolism 1 (1999), 265.
2. R.S. Kellar, L.K. Landeen, B.R. Shepherd et al. Scaffold-Based, Three-Dimensional, Human Fibroblast Culture Provides a Structural Matrix That Supports Angiogenesis in Infarcted Heart Tissue, Circulation 104 (2001), 2063.
3. R.S. Kellar, B.R. Shepherd, G.K. Naughton et al., A Cardiac Patch Constructed from Human Fi-broblasts Attenuates A Reduction In Cardiac Function Following Acute Infarct, Tissue Engineering 11 (2005), 1678.